BioPharma Resources

Drug Trial Radar · NCT07245446

A Study of Ivonescimab in First-Line ES-SCLC

A Phase II Clinical Study of Ivonescimab Combination Therapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). The main questions the study aims to answer are: * What side effects do participants experience from these combination treatments? * How well do the treatments work to shrink tumors? Researchers will compare three groups to see which combination works best. All participants will receive Ivonescimab and chemotherapy (etoposide and carboplatin). The differences are: * Group 1 will also receive an additional drug called AK117. * Group 2 will also receive a different additional drug called Cadonilimab. * Group 3 will receive Ivonescimab and chemotherapy only. Participants will: * Be assigned by chance to one of the three groups. * Undergo an initial treatment phase (about 3 months), receiving chemotherapy plus the specific study drugs for their group. * If the treatment is effective and side effects are manageable, continue with a maintenance phase using only the study drugs (without chemotherapy) for up to 2 years. * Attend regular clinic visits for check-ups, blood tests, and imaging scans (like CT scans) to see how they are responding to the treatment.

Conditions

  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

  • IvonescimabDrug

    Administered intravenously at a specified dose and frequency.

  • CadonilimabDrug

    Administered intravenously at a specified dose and frequency.

  • AK117Drug

    Administered intravenously at a specified dose and frequency.

  • EtoposideDrug

    Administered intravenously at 100 mg/m² on Days 1-3 of each 3-week cycle for 4 cycles.

  • Carboplatin (AUC 5)Drug

    Administered intravenously at AUC 5 on Day 1 of each 3-week cycle for 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 2 years.
  2. Incidence of Adverse Events (AEs)Time frame: From first dose up to 90 days after last dose.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Shanghai Pulmonary Hospital Affiliated to Tongji University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.